JP2018528263A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528263A5
JP2018528263A5 JP2018527025A JP2018527025A JP2018528263A5 JP 2018528263 A5 JP2018528263 A5 JP 2018528263A5 JP 2018527025 A JP2018527025 A JP 2018527025A JP 2018527025 A JP2018527025 A JP 2018527025A JP 2018528263 A5 JP2018528263 A5 JP 2018528263A5
Authority
JP
Japan
Prior art keywords
composition
compound
subject
need
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018527025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528263A (ja
JP7054674B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/001244 external-priority patent/WO2017025802A1/en
Publication of JP2018528263A publication Critical patent/JP2018528263A/ja
Publication of JP2018528263A5 publication Critical patent/JP2018528263A5/ja
Priority to JP2021181238A priority Critical patent/JP2022023215A/ja
Application granted granted Critical
Publication of JP7054674B2 publication Critical patent/JP7054674B2/ja
Priority to JP2024010113A priority patent/JP2024050701A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018527025A 2015-08-11 2016-08-11 Ｄｐｅｐ－１結合組成物および使用の方法 Active JP7054674B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021181238A JP2022023215A (ja) 2015-08-11 2021-11-05 Ｄｐｅｐ－１結合組成物および使用の方法
JP2024010113A JP2024050701A (ja) 2015-08-11 2024-01-26 Ｄｐｅｐ－１結合組成物および使用の方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562203704P 2015-08-11 2015-08-11
US62/203,704 2015-08-11
US201562264032P 2015-12-07 2015-12-07
US62/264,032 2015-12-07
PCT/IB2016/001244 WO2017025802A1 (en) 2015-08-11 2016-08-11 Dpep-1 binding compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021181238A Division JP2022023215A (ja) 2015-08-11 2021-11-05 Ｄｐｅｐ－１結合組成物および使用の方法

Publications (3)

Publication Number Publication Date
JP2018528263A JP2018528263A (ja) 2018-09-27
JP2018528263A5 true JP2018528263A5 (https=) 2019-09-19
JP7054674B2 JP7054674B2 (ja) 2022-04-14

Family

ID=57983413

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018527025A Active JP7054674B2 (ja) 2015-08-11 2016-08-11 Ｄｐｅｐ－１結合組成物および使用の方法
JP2021181238A Pending JP2022023215A (ja) 2015-08-11 2021-11-05 Ｄｐｅｐ－１結合組成物および使用の方法
JP2024010113A Pending JP2024050701A (ja) 2015-08-11 2024-01-26 Ｄｐｅｐ－１結合組成物および使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021181238A Pending JP2022023215A (ja) 2015-08-11 2021-11-05 Ｄｐｅｐ－１結合組成物および使用の方法
JP2024010113A Pending JP2024050701A (ja) 2015-08-11 2024-01-26 Ｄｐｅｐ－１結合組成物および使用の方法

Country Status (8)

Country Link
US (3) US10493127B2 (https=)
EP (2) EP4643873A3 (https=)
JP (3) JP7054674B2 (https=)
AU (3) AU2016305299B2 (https=)
CA (2) CA2999800C (https=)
ES (1) ES3057215T3 (https=)
IL (2) IL305285A (https=)
WO (1) WO2017025802A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3057215T3 (en) * 2015-08-11 2026-02-26 Arch Biopartners Inc Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
AU2017281744B2 (en) * 2016-06-24 2022-10-27 Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón Cilastatin for use in the treatment of sepsis
JP7535514B2 (ja) * 2018-11-30 2024-08-16 アーチ バイオパートナーズ， インコーポレイテッド Ｄｐｅｐ－１結合剤および使用の方法
KR102730193B1 (ko) * 2020-07-24 2024-11-14 신규철 단일성분의 마이크로구조체 색전물질과 그 색전물질을 이용한 색전술로 시행되는 치료방법
KR102486996B1 (ko) * 2020-09-04 2023-01-10 서울대학교병원 펩타이드 및 이를 포함하는 피부 주름 개선용 조성물 및 대사성 질환 치료용 조성물
EP4320167A4 (en) * 2021-04-08 2025-08-06 Nat Res Council Canada DPEP-1 BINDING AGENTS AND METHODS OF USE THEREOF

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5629179A (en) 1995-03-17 1997-05-13 Novagen, Inc. Method and kit for making CDNA library
US5698401A (en) 1995-11-14 1997-12-16 Abbott Laboratories Use of nuclear magnetic resonance to identify ligands to target biomolecules
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
US6174687B1 (en) 1999-02-26 2001-01-16 The Burnham Institute Methods of identifying lung homing molecules using membrane dipeptidase
ES2313779T3 (es) 1998-03-13 2009-03-01 The Burnham Institute Moleculas que migran a diversos organos o tejidos seleccionados.
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US6927212B2 (en) 2002-07-27 2005-08-09 The Johns Hopkins University Design and synthesis of renal dipeptidase inhibitors
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2006010496A1 (en) 2004-07-28 2006-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidase 1 (dpep1)
EP3461499A1 (en) 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
EP2196212A4 (en) 2007-10-04 2012-01-25 Josai University Corp PREPARATION AND METHOD FOR THE ADMINISTRATION OF A VACCINE AND IONTOPHORESE DEVICE WITH THE PREPARATION
WO2010004060A1 (es) * 2008-07-11 2010-01-14 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon Uso de la cilastatina para reducir la nefrotoxicidad de distintos compuestos
WO2010099084A2 (en) 2009-02-27 2010-09-02 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules
EP2544528A1 (en) 2010-03-09 2013-01-16 Merck Sharp & Dohme Corp. FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS
EP4012714A1 (en) 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2015120536A1 (en) 2014-02-13 2015-08-20 Arch Cancer Therapeutics, Inc. Peptides that block leukocyte recruitment and methods of use
ES3057215T3 (en) * 2015-08-11 2026-02-26 Arch Biopartners Inc Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
AU2017281744B2 (en) 2016-06-24 2022-10-27 Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón Cilastatin for use in the treatment of sepsis

Similar Documents

Publication Publication Date Title
JP2018528263A5 (https=)
Saliba et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: a multicenter randomized trial
Garcia-Sanz et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Petruzziello-Pellegrini et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin–associated hemolytic uremic syndrome in humans and mice
JP7445893B2 (ja) ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ
Zeller et al. A novel phosphocholine‐mimetic inhibits a pro‐inflammatory conformational change in C‐reactive protein
Berger et al. Update on C1 esterase inhibitor in human solid organ transplantation
US9056098B2 (en) Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
ShamsEldeen et al. Resveratrol suppresses cholestasis‐induced liver injury and fibrosis in rats associated with the inhibition of TGFβ1–Smad3–miR21 axis and profibrogenic and hepatic injury biomarkers
IL263123B (en) Compounds for use in targeting cancer stem cells in the adjuvant or neoadjuvant treatment of cancer
JP2018516944A5 (https=)
Yadav et al. Remediation of hemorrhagic shock-induced intestinal barrier dysfunction by treatment with diphenyldihaloketones EF24 and CLEFMA
JP2016537380A5 (https=)
CN107405316A (zh) 用于治疗原发性激素耐受性子宫内膜癌和乳腺癌的方法
JP2005537245A5 (ja) プロテイナーゼ活性化レセプターのアンタゴニストを含む組成物および方法
AU2022474010A1 (en) Compositions for and methods of precision cancer treatment
Cheah et al. Front‐line management of indolent non‐Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma
CA3130518A1 (en) Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
WO2022149605A1 (ja) 重症肺高血圧症、治療抵抗性肺高血圧症、又は薬剤性肺高血圧症の予防又は治療薬
Roh et al. Identification and characterization of warm temperature acclimation proteins (Wap65s) in rainbow trout (Oncorhynchus mykiss)
JP2017508734A5 (https=)
Wen et al. HLA-DR overexpression in tubules of renal allografts during early and late renal allograft injuries
JP2018500879A5 (https=)
JPWO2021066062A5 (https=)
Sihag et al. Natural IgM blockade limits infarct expansion and left ventricular dysfunction in a swine myocardial infarct model